Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication of Audited Financial Results for the financial year ended 31 March, 2026

Marksans Pharma submitted newspaper advertisements of its audited financial results for the quarter and year ended March 31, 2026, published on May 27, 2026 in Business Standard (English) and Lakshadeep (Marathi). The filing is under SEBI LODR Regulation 47. The actual financial numbers are embedded in the newspaper notice along with results from other companies (Suraj Products Limited). Suraj Products (consolidated) reported total income of Rs 9,938.31 lakh for Q4 FY26 vs Rs 6,574.90 lakh in Q3, and full-year income of Rs 30,488.10 lakh. Net profit after tax for Q4 was Rs 688.84 lakh (standalone: Rs 701.42 lakh on income of Rs 9,950.60 lakh). Full-year standalone net profit after tax was Rs 1,884.79 lakh vs Rs 2,143.39 lakh in FY25, indicating a decline in annual profit. Suraj Products also recommended a final dividend of Rs 2.25 per equity share (22.5% on face value Rs 10) subject to shareholder approval at the AGM.